Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sponsor's decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a retrospective record review to determine whether a novel multiplex PCR assay can be utilized as a screening method for UTI in patients receiving Botox injection to treat overactive bladder (OAB).
The novel multiplex real-time PCR assay with mixed floral antibiotic resistance profiling offers a higher degree of sensitivity and specificity than conventional culture methods in the identification of UTI pathogens as determined by a previous prospective comparison study. This is a retrospective record review comparing PCR and culture-based assessments for UTI in patients receiving Botox injection to treat overactive bladder (OAB). Investigators aim to determine whether M-PCR/P-AST can be utilized as a screening method for UTI in these patients and whether whether antibiotic prophylaxis, peri-procedural antibiotics, and post-injection antibiotic therapy based on patients' pre-procedural M-PCR/P-AST results in improved response to Botox injection compared to standard of care. The attributes and advantages of PCR testing over the use of traditional urine cultures, and the potential identification of polymicrobial infections with complicated resistance sharing mechanisms, may significantly improve patient care.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard Pre-Procedural Urine Culture | This is a control cohort that follows standard pre-procedural protocol by implementing antibiotic prophylaxis and treatment regimens based on dipstick urine analysis (UA) followed by reflexed traditional urine culture and sensitivity (C&S) methods performed before injection. |
| |
| Pre-Procedural M-PCR/P-AST | This is an experimental cohort that implements Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST) for pre-procedural UTI screening. The cohort follows an antibiotic treatment regimen based on the results of M-PCR/P-AST. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST) | Diagnostic Test | M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance. |
| Measure | Description | Time Frame |
|---|---|---|
| Post procedural UTI | Defined as development of UTI confirmed by urine culture/PCR in the setting of UTI symptoms requiring antibiotic therapy | Up to 3 weeks post injection |
| Recurrent UTI | Defined as the development of multiple UTI confirmed by urine culture/PCR in the setting of UTI symptoms requiring antibiotic therapy | Up to 12 months post-injection |
| Resistant UTI | Defined as UTI that manifests as a persistence or worsening of symptoms during antibiotic course | Up to 12 months post-injection |
| Antibiotic Usage | Defined as total number of post-procedural antibiotics ordered/taken within 3 weeks post BOTOX injection | Up to 3 weeks post-injection |
| Visit Reschedule/Cancellation Rate | Defined as any injection visit cancelled/postponed/rescheduled due to results of preprocedural assessments (abnormal UA, lower urinary tract symptoms etc.) | Up to 1 year after pre-procedural assessment |
| Measure | Description | Time Frame |
|---|---|---|
| UTI-related ED Visit Rate | Defined as any visit to the ED relating to symptoms of UTI within 3 weeks post-Botox injection | Up to 3 weeks post-injection |
| UTI-hospital Admission Rate | Defined as any admission to the hospital (from home/ED or clinic transfer) relating to symptoms of UTI within 3 weeks post-Botox injection |
Not provided
Inclusion/Exclusion Criteria:
Not provided
Not provided
Not provided
Patients receiving Botox injections for the treatment of neurogenic or non-neurogenic OAB
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Baunoch, PhD | Pathnostics, Inc. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Comprehensive Urologic Care | Barrington | Illinois | 60010 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014552 | Urinary Tract Infections |
| D053201 | Urinary Bladder, Overactive |
| ID | Term |
|---|---|
| D007239 | Infections |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
| Urine Culture | Diagnostic Test | A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods. |
|
| Up to 3 weeks post-injection |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |